Insights from 2024 EHA Annual Meeting
M

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory WM/LPL

By Insights from 2024 EHA Annual Meeting FEATURING Mazyar Shadman
By Insights from 2024 EHA Annual Meeting FEATURING Mazyar Shadman
59 views
June 28, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Related Content

AUTOPLAY
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
17:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…

Feat. M. Minnema
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
25:22
Integrity CE

Treatment Updates and Management of Non-Hodgkin Lymphomas

Feat. D. Wallace, M. Cortese
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
16:27
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Therapeutic Advances in T-Cell Lymphoma in 2024

Feat. S. Barta
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

19:00
Indy Hematology Review

Waldenstrom’s Macroglobulinemia: Approaching the Newly Diagnosed and…

Feat. S. Treon
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
05:38
GRACE

Epcoritamab in NHL - Incidence and Management of CRS

Feat. T. Phillips
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
22:38
Indy Hematology Review

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Feat. T. Phillips
15:03
SOHO 2023 Eleventh Annual Meeting

Novel Combinations in Indolent Lymphoma

Feat. P. Strati
13:58
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Feat. M. Salamoon
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

20:25
SOHO Brazil 2024

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

Feat. A. Zelenetz